Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib

CONCLUSIONS: The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.PMID:38512101 | DOI:10.1080/13696998.2024.2333683

Source: Journal of Medical Economics - March 21, 2024 Category: Health Management Authors: Masayuki Saruta Isao Kawaguchi Yuji Ogawa Yuri Sanchez Gonzalez Naoki Numajiri Xiaohe Tang Russell Miller Source Type: research